Eli Lilly releases promising early-stage data on an ADC for ovarian cancer
FROM THE WIRE · SEEKINGALPHA.COM
[Ovarian malignant tumor, Female uterus anatomy, Reproductive system, cancer cells, ovaries cysts, cervical cancer, growing cells, gynecological disease, metastasis cancerous, duplicating, 3d render] ALIOUI Mohammed Elamine * Phase 1 data on Eli Lilly's (LLY…
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishPositive phase 1 data on a candidate drug from a large pharma group, relevant for the LLY stock.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Phase 1 data cover sofetabart mipitecan (Sofe-M) combined with bevacizumab in platinum-sensitive ovarian cancer.
- 02The reported confirmed objective response rate is 79%, with a 100% disease control rate.
- 03Participants had a median of three prior systemic regimens.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets